Several types of medicines are used to manage type 2 diabetes. Some help the body release insulin, while others reduce the amount of glucose reabsorbed by the kidneys.
Two important groups are GLP-1 receptor agonists and SGLT2 inhibitors. Both help lower blood sugar, but they work through different mechanisms and offer additional health benefits.
GLP-1 medicines influence hormones involved in insulin release, appetite and digestion. SGLT2 inhibitors work through the kidneys to remove excess glucose from the blood.
Understanding GLP-1 vs SGLT2 inhibitors can help you learn why a doctor may recommend one medicine or sometimes both as part of a diabetes treatment plan.
Table of Contents
What Are GLP-1 Receptor Agonists?
GLP-1 stands for glucagon-like peptide-1. It is a natural hormone released by the intestine after eating. It helps regulate blood sugar by stimulating insulin release when glucose levels are high.
GLP-1 receptor agonists are prescription medicines that mimic this hormone. They activate GLP-1 receptors and help the body manage blood glucose.
These medicines work by:
- Increasing insulin release when blood sugar is elevated.
- Reducing glucagon secretion, which limits glucose release from the liver.
- Slowing stomach emptying with some medicines.
- Reducing appetite and increasing feelings of fullness.
Examples include semaglutide, liraglutide, dulaglutide, exenatide and lixisenatide.
Depending on the medicine and formulation, GLP-1 treatments may be available as daily or weekly injections. Oral semaglutide is also available for certain approved uses.
What Are SGLT2 Inhibitors?
SGLT2 stands for sodium-glucose cotransporter-2. It is a protein found mainly in the kidneys that helps reabsorb glucose from urine back into the bloodstream.
SGLT2 inhibitors block this protein, allowing more glucose to leave the body through urine. This helps lower blood sugar independently of insulin.
Common SGLT2 inhibitors include:
- Dapagliflozin
- Empagliflozin
- Canagliflozin
- Ertugliflozin
These medicines are generally taken as oral tablets, usually once daily. Their approved uses and recommended doses depend on the specific medicine and a person’s health conditions.
GLP-1 vs SGLT2 Inhibitors: Key Differences
Both medicine groups help manage type 2 diabetes, but their effects on the body differ.
| Feature | GLP-1 receptor agonists | SGLT2 inhibitors |
| Main action | Activate GLP-1 receptors | Block glucose reabsorption in the kidneys |
| Blood sugar control | Generally strong, depending on the medicine | Varies with kidney function and medicine |
| Weight effect | Often support greater weight loss | Usually cause modest weight loss |
| Administration | Oral or injectable, depending on medicine | Oral tablets |
| Heart benefits | Certain medicines reduce cardiovascular risks | Certain medicines reduce heart failure risks |
| Kidney benefits | Certain medicines offer kidney-related benefits | Several medicines slow chronic kidney disease progression |
| Low blood sugar risk | Low when used alone | Low when used alone |
| Common side effects | Nausea, vomiting and diarrhoea | Genital fungal infections, increased urination and dehydration |
The main difference is that GLP-1 medicines work through hormone receptors, while SGLT2 inhibitors work through the kidneys. Both can provide benefits beyond blood sugar control, but these benefits vary by medicine.
Benefits of GLP-1 Receptor Agonists
GLP-1 medicines may be useful for people who need better blood sugar control along with support for weight management.
- Effective blood sugar management
These medicines help the body release insulin when blood glucose levels rise. They also reduce glucagon secretion, helping prevent excessive glucose release from the liver.
- Support for weight loss
GLP-1 receptor agonists can reduce appetite and increase feelings of fullness. This may help people eat smaller portions and lose weight over time.
People exploring additional approaches to managing excess weight can learn about available weight-loss treatment options.
- Potential cardiovascular benefits
Certain GLP-1 medicines have demonstrated a reduction in major cardiovascular events in specific groups of people with type 2 diabetes. This may be an important consideration for patients with existing cardiovascular disease or increased risk.
- Low risk of hypoglycaemia
When used alone, GLP-1 medicines generally have a low risk of causing hypoglycaemia, or low blood sugar. The risk may increase when they are combined with insulin or certain other diabetes medicines.
Benefits of SGLT2 Inhibitors
SGLT2 inhibitors offer benefits beyond lowering blood glucose. They may be particularly useful for people with type 2 diabetes who also have heart failure or chronic kidney disease.
- Blood sugar control
By helping the kidneys remove excess glucose through urine, SGLT2 inhibitors reduce blood sugar levels. Their glucose-lowering effect may become weaker as kidney function declines.
- Heart failure protection
Certain SGLT2 inhibitors reduce the risk of hospitalisation for heart failure. They may be recommended to eligible patients with heart failure, even when additional blood sugar reduction is not the main treatment goal.
- Kidney protection
SGLT2 inhibitors can slow the progression of chronic kidney disease in eligible patients. Their kidney benefits are not limited to their effect on blood sugar.
- Modest weight and blood pressure reduction
As glucose and some calories are removed through urine, people may experience modest weight loss. These medicines can also help reduce blood pressure in some patients.
Can GLP-1 and SGLT2 Inhibitors Be Used Together?
Yes. Doctors may prescribe GLP-1 receptor agonists and SGLT2 inhibitors together for some people with type 2 diabetes.
These treatments work through different mechanisms. GLP-1 medicines influence insulin release, appetite and digestion, while SGLT2 inhibitors help the kidneys remove excess glucose.
Combining them may provide complementary benefits, including:
- Improved blood sugar control.
- Additional support for weight management.
- Cardiovascular risk reduction with medicines that have proven benefits.
- Kidney protection in eligible patients.
However, combination treatment is not necessary for everyone. A doctor will assess kidney function, existing medications and individual treatment goals before recommending it.
Possible Side Effects of GLP-1 and SGLT2 Inhibitors
Both medicine groups can cause side effects, although their effects on the body differ.
| GLP-1 receptor agonists | SGLT2 inhibitors |
| Nausea and vomiting | Genital fungal infections |
| Diarrhoea or constipation | Increased urination |
| Abdominal discomfort | Dehydration |
| Reduced appetite | Dizziness due to low blood pressure |
| Possible gallbladder problems | Urinary tract infections |
GLP-1 medicines may also be associated with gallbladder problems and, rarely, pancreatitis. Severe or persistent abdominal pain should be evaluated by a doctor.
SGLT2 inhibitors can rarely cause diabetic ketoacidosis, sometimes even when blood sugar is not very high. The risk may increase during prolonged fasting, severe illness, surgery or dehydration. Doctors may advise temporarily stopping these medicines before certain procedures or during specific illnesses.
Never stop or change your treatment without medical advice.
Which Is Better for Type 2 Diabetes?
There is no single medicine that is best for everyone. The choice depends on blood sugar levels, weight, heart health, kidney function and treatment goals.
| Patient requirement | Treatment a doctor may consider |
| Greater weight-loss support | GLP-1 receptor agonist |
| Type 2 diabetes with heart failure | SGLT2 inhibitor with proven benefit |
| Type 2 diabetes with chronic kidney disease | SGLT2 inhibitor and/or GLP-1 medicine with proven kidney benefit |
| Need for stronger blood sugar reduction | GLP-1 receptor agonist, depending on the medicine |
| Complementary heart and kidney benefits | Combination of both, when appropriate |
For people with obesity, doctors may also discuss other weight-management approaches depending on medical eligibility. These may include bariatric surgery, an intragastric balloon procedure or suitable weight-loss surgery options. These procedures are separate weight-management interventions and are not substitutes for diabetes medicines.
Frequently Asked Questions
- Are GLP-1 and SGLT2 inhibitors the same?
No. GLP-1 medicines activate hormone receptors to improve insulin release and support appetite control. SGLT2 inhibitors block glucose reabsorption in the kidneys, allowing more glucose to leave the body through urine.
- Which is better for weight loss: GLP-1 or SGLT2 inhibitors?
GLP-1 receptor agonists generally produce greater weight loss. SGLT2 inhibitors usually cause more modest weight reduction. Results depend on the specific medicine and individual response.
- Can GLP-1 and SGLT2 inhibitors be taken together?
Yes. Doctors may prescribe both because they work differently and can provide complementary benefits. However, this combination is appropriate only for certain patients.
- Do SGLT2 inhibitors protect the kidneys?
Certain SGLT2 inhibitors have demonstrated benefits in slowing chronic kidney disease progression. They may be prescribed for eligible patients with kidney disease, including some who do not have diabetes.
- Do GLP-1 and SGLT2 inhibitors cause low blood sugar?
Both groups have a relatively low risk of hypoglycaemia when used alone. However, the risk may increase when they are combined with insulin or certain other diabetes medicines.
Conclusion
GLP-1 receptor agonists and SGLT2 inhibitors are two important treatment options for type 2 diabetes. While GLP-1 medicines support insulin release and weight management, SGLT2 inhibitors help the kidneys remove excess glucose and offer important heart and kidney benefits with certain medicines.
In some cases, doctors may recommend both treatments to address different health needs. The right approach depends on medical history, kidney function, cardiovascular health and individual treatment goals.
Consult a qualified diabetologist to understand which treatment is appropriate for your condition. A personalised plan can help manage blood sugar while supporting long-term health.
